Yamikani Ndasauka, Halima Sumayya Twabi, Jimmy Kainja, Anthony Mavuto Gunde, Catherine Makhumula-Mtimuni
Knowledge, attitudes and demographic drivers for COVID-19 vaccine hesitancy in Malawi
Scientific reports
background benralizumab shown restore good control severe eosinophilic asthma sea robust data benralizumab effectiveness periods longer 2 years scarce methods retrospective multicentric study conducted 108 italian sea patients treated benralizumab 36 months partial complete clinical remission cr assessed data analyzed descriptive statistics using linear logistic negative binomial mixedeffect regression models results 36 months benralizumab reduced exacerbation rate 89 increased forced expiratory volume 1 second fev1 440 ml 36 months p 00001 benralizumab improved asthma control well sinonasal symptoms patients chronic rhinosinusitis nasal polyposis crswnp 9333 patients either reduced discontinued ocs benralizumab also decreased ics use asthma medications overall 8431 patients achieved partial complete cr conclusions benralizumab improved asthma sinonasal outcomes 36 months findings support potential benralizumab induce cr emphasizing role diseasemodifying antiasthmatic drug management sea research warranted expand findings minimizing data loss assessing benralizumabs longterm safety